ArticleCardiovascular drugs and therapy2026
Shenfu Injection Inhibits Cardiac Fibroblast Activation and Improves Myocardial Fibrosis by Down-regulating M1 Macrophage-Derived Exosomal miR-155-5p.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeMyocardial fibrosis is a key pathological feature of heart failure (HF) linked to aberrant macrophage polarization. Although the traditional Chinese medicine Shenfu injection (SFI) clinically improves HF and has been found to inhibit M1 macrophage polarization and fibrosis, its mechanisms remain unclear. This study aimed to elucidate how SFI regulates macrophage-cardiac fibroblasts (CFs) communication - specifically via exosomal miR-155-5p from M1 macrophages.
methodsAn isoproterenol (ISO)-induced mouse model of HF was established to assess the effects of SFI on cardiac function, inflammatory cytokines, myocardial fibrosis, and the expression and localisation of miR-155-5p. In vitro, an M1 macrophage model was generated using lipopolysaccharide (LPS)-stimulated RAW264.7 cells, which were then treated with SFI or an miR-155-5p inhibitor. Exosomes from these cells were isolated and co-cultured with CFs to evaluate the miR-155-5p/SOCS1 pathway and fibrosis markers.
resultsmiR-155-5p expression was markedly upregulated and localized to infiltrating cardiac macrophages in mice. SFI treatment reduced levels of TNF-α, IL-6, and miR-155-5p, along with improved fibrosis and cardiac function. In vitro, SFI significantly decreased miR-155-5p levels in exosomes derived from M1 macrophages. Co-culture with exosomes from macrophages that were either SFI-treated or miR-155-5p-inhibited suppressed CFs activation. This was demonstrated by reduced expression of fibrosis markers (α-SMA, Col I, Col III), as well as decreased miR-155-5p levels and restored SOCS1 expression.
conclusionThis study demonstrates that SFI alleviates myocardial fibrosis by suppressing macrophage-derived exosomal miR-155-5p and restoring SOCS1 in CFs, thereby providing a mechanistic basis for its established clinical efficacy in HF. Our findings highlight the potential of targeting the macrophage-fibroblast miR-155-5p/SOCS1 axis as a therapeutic strategy.
Indexed as
Identifiers
42313305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.